Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer.

H. Wilke(Kliniken Essen-Mitte), A. Harstrick(Merck KGaA, Darmstadt (Germany)), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), H. Knipp(Alfried Krupp Hospital), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Meyer Hj, Köhne-Wömpner Ch, P. Preusser(University Hospital Münster), U. Fink, W. Achterrath(Messer (Germany))

PubMed

April 1, 1992

Cited by 9

Related Papers

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

|Annals of Oncology|2012|1.5k

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

|The Lancet Oncology|2012|526

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

|Journal of Clinical Oncology|2005|491

Characterization of the rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis

|Genes & Development|2009|351

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

|Annals of Oncology|2016|344